Engineered immune cells target CD70 in kidney cancer
NCT ID NCT06480565
First seen Sep 10, 2026 · Last updated Sep 11, 2026 · Updated 1 time
Summary
Researchers are testing a new cell therapy called ADI-270 in adults with clear cell renal cell carcinoma that has come back or stopped responding to standard treatments. ADI-270 uses engineered gamma-delta T cells that carry a chimeric receptor to seek out and attack cancer cells displaying a marker called CD70. The trial aims to find a safe dose and see how well the therapy works. Participants first receive chemotherapy to make room for the cells, then the ADI-270 infusion.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70
- What this could lead to
- If it works, this could offer a new treatment option for people whose clear cell kidney cancer has come back or stopped responding to standard drugs.
- What could go wrong
- This is an early-phase trial with about 60 participants, so researchers mainly want to find a safe dose. The therapy may cause serious side effects, and it may not shrink tumors.
Why investors are watching
Adicet Bio runs this Phase 1/2 trial of ADI-270, an engineered gamma-delta CAR Vδ1 T cell therapy that targets CD70, in adults with relapsed or refractory clear cell renal cell carcinoma. The study tests dose escalation and dose expansion across 60 planned participants. For a micro-cap company, this readout carries the whole story: it is the main evidence that the platform works in patients.
If it works: A positive result could support further development of ADI-270 and draw partner or financing interest. It may also validate the company's engineered gamma-delta T cell approach beyond this one cancer.
If it fails: Early-phase trials often fail on safety, tolerability, or signs of benefit. A failure or delay could leave the company with limited clinical momentum and few other late-stage assets.
AI-written from the trial record. Speculative, and not investment advice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1/2
Runs two stages together: safety and dose first, then whether the treatment works.
- Participants
-
About 60 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2024
- Expected to finish
-
Jun 2027
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Histologically or cytologically confirmed clear cell RCC 2. Documented evidence of advanced or metastatic diseases. 3. Patients must have been treated with an immune checkpoint inhibitor and a VEGF inhibitor (the VEGF inhibitor must have been administered in the advanced and/or metastatic setting). 4. At least one measurable target lesion according to RECIST 1.1 5. At least three weeks, or 5 half-lives, whichever is shorter, from the last dose of the prior line of systemic therapy 6. KPS ≥ 70 Exclusion Criteria: 1. Subjects with CNS metastases or spinal cord compression are not eligible, unless they have completed therapy and have discontinued the use of corticosteroids for at least 8 weeks and remained stable prior to enrollment. 2. Clinically significant CNS dysfunction of any etiology in the opinion of the Investigator. 3. Prior radiation therapy within 21 days prior to start of study treatment with the exception of palliative radiotherapy to bone lesions (palliative radiotherapy to bone lesions must be completed at least 2 weeks prior to the first dose of LD). 4. Active malignancy (except for RCC, definitively treated basal or squamous cell carcinoma of the skin, and carcinoma in-situ of the cervix or bladder) within the past 24 months 5. Treatment with gene therapy, genetically modified cell therapy, or adoptive T cell therapy within 6 weeks before initiating LD in this study. 6. Receipt of CD70 targeted therapies for any indication 7. Require corticosteroid therapy \> 5 mg per day of prednisone or equivalent. 8. History of any form of primary immunodeficiency such as severe combined immunodeficiency disease. 9. Presence of active autoimmune disease requiring ongoing systemic immunosuppressive therapy.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Clear cell renal cell carcinoma are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Adicet Clinical Trials
Redwood City, California, 94065, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a year of sunitinib delay kidney Cancer's return after lung surgery?
- Can a Patient's own immune cells beat advanced kidney cancer?
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return